Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The cost of Alzheimer’s

Executive Summary

The Congressional Budget Office estimates that the Alzheimer's Breakthrough Act of 2007 would authorize the appropriation of $24 million in fiscal year 2008 with an estimated $3.9 billion in total appropriations expected through 2012. The Act, sponsored by Sens. Barbara Mikulski, D-Md., and Kit Bond, R-Mo., would provide more funds for disease research, public education and an Alzheimer's call center, as well as state demonstration projects. Though no legislative action is planned for the bill, FDA plans to hold an Oct. meeting with neurology organizations to discuss drug treatments and biomarker developments for the disease (1"The Pink Sheet" Aug. 13, 2007, p. 10)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel